ClinicalTrials.gg
CompletedNCT05230537Updated Oct 27, 2026

A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration

A Phase 2 interventional study of Iptacopan (LNP023) and Placebo in Age-Related Macular Degeneration, sponsored by Novartis Pharmaceuticals. Completed at 28 sites in 4 countries. Open to participants aged 50 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Updated Oct 27, 2026Now CompletedPrimary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
168
Allocation
Randomized
Ages
50 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 81 studies in Macular Degeneration by Novartis — 1 open to participants now, 1 under way, none of them phase 3. Macular Degeneration · Novartis.

Enrollment
24th of 56
168 · median 129
Started
2022
with 8 others
Phase 2
9 of 81
1 open now
Registered
72nd of 81
by date

Among the 81 studies in Macular Degeneration by Novartis, this one is the 24th largest by enrollment of the 56 interventional ones that give a count, is one of 9 that started in 2022, is one of 9 in phase 2, and was the 72nd registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

1 of the 81 studies in Macular Degeneration by Novartis is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Macular Degeneration by Novartis, or all of them as a file.
02

Study summary

The purpose of this study is to assess the effect of Iptacopan to prevent conversion of early or intermediate age-related macular degeneration (AMD) eyes to new incomplete retinal pigment epithelium and outer retinal atrophy (iRORA) or late AMD.

Read the detailed description

This is a multicenter, randomized, participant and investigator masked, placebo controlled, proof-of-concept study to assess the safety and efficacy of Iptacopan (LNP023) in participants with early to intermediate age-related macular degeneration in one eye and neovascular age-related macular degeneration in the other eye. All enrolled participants must have early/intermediate AMD in one eye, with at least one high risk optical coherence tomography (OCT) feature (study eye) and neovascular AMD in the other eye (fellow eye).

Participants who meet all of the eligibility criteria will be randomized at the Baseline/Day 1 visit in a 1:1 ratio into one of two treatment arms:

  • Iptacopan (LNP023) oral capsules
  • Placebo oral capsules Approximately 146 participants (73 per arm) will be treated worldwide.
03

Conditions studied

  • Age-Related Macular Degeneration

Keywords

  • Age-related macular degeneration
  • Macular degeneration
  • vision loss, macula damage
  • retina damage
  • dry macular degeneration
  • wet macular degeneration
  • AMD
  • Best Corrected Visual Acuity
  • Neovascular AMD
  • OCT
04

Who can participate

Ages eligible
50 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants ≥ 50 years of age
  • Diagnosis of early or intermediate age-related macular degeneration (AMD) in the study eye as determined by the investigator on fundus examination
  • Study eye (early/intermediate AMD eye) must have at least one high risk optical coherence tomography (OCT) feature (as defined by a central reading center).
  • Diagnosis of neovascular AMD (nAMD) in the fellow eye as determined by the investigator.
  • Vaccination against Neisseria meningitidis and Streptococcus pneumoniae infection are required prior to the start of the treatment with LNP023.
  • If not received previously, vaccination against Haemophilius influenzae infection should be given, if available and according to local regulations.

Exclusion criteria

Exclusion Criteria:

  • History or current diagnosis of abnormalities indicating significant safety risk, such as cardiac arrhythmias, e.g., sustained ventricular tachycardia and clinically significant second or third degree atrioventricular block (AV block) without a pacemaker.
  • History of familial long syndrome or known family history of Torsades de Pointes
  • History of stroke or myocardial infarction during the 6-month period prior to Baseline/Day 1, any current clinically significant arrhythmias, or any advanced cardiac or severe pulmonary hypertension
  • History of end stage kidney disease requiring dialysis or renal transplant
  • History of of any organ system
  • History of solid organ or bone marrow transplantation
  • History of recurrent meningitis or history of meningococcal infections despite vaccination
  • History of immunodeficiency diseases, including a positive test result at Screening
  • Active (HBV) or (HCV) infection
  • History of to any of the study treatments or or to drugs of similar chemical classes or clinically relevant sensitivity to fluorescein dye as assessed by the Investigator.
  • Evidence of cRORA or exMNV in the study eye based on multimodal imaging as determined by the central reading center.
  • Participants who have current active TB as evidenced by clinical, radiographic and laboratory tests.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
168 participants (actual)

Study arms

  • Experimental
    Iptacopan (LNP023)

    Iptacopan (LNP023) oral use capsules

    Drug: Iptacopan (LNP023)

  • Placebo comparator
    Placebo

    Placebo matched to study drug, oral use capsules

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Development of new incomplete retinal pigment epithelium & outer retinal atrophy or late age-related macular degeneration (AMD) in the early/intermediate AMD eye as determined by optical coherence tomography (OCT) & supported by multimodal imaging

    OCT and other imaging will be performed using spectral domain OCT or swept source OCT machines

    Time frame: Baseline/Day 1 through Month 24

Secondary outcomes

  1. The incidence of ocular and non-ocular adverse events (AEs)

    An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a clinical investigation participant after providing written informed consent for participation in the study.

    Time frame: Baseline/Day 1 through Month 24

  2. Change in Early Treatment Diabetic Retinopathy Study (ETDRS) (Standard Luminance) best corrected visual acuity (BCVA) scores in the early/intermediate AMD eye

    Best corrected visual acuity (BCVA) will be measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart. The number of letters read correctly, for each eye, will be recorded. Participants at sites in some countries may conduct BCVA testing using numerical charts rather than letter charts.

    Time frame: Baseline/Day 1 through Month 24

  3. Change in ETDRS low luminance visual acuity (LLVA) scores in the early/intermediate AMD eye

    ETDRS low luminance visual acuity (LLVA) scores will be measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart. The number of letters read correctly, for each eye, will be recorded. Participants at sites in some countries may conduct BCVA testing using numerical charts rather than letter charts.

    Time frame: Baseline/Day 1 through Month 24

  4. Change in contrast sensitivity (CS) scores in the early/intermediate AMD eye

    Pelli-Robson contrast sensitivity measurements will be performed using a Pelli-Robson contrast sensitivity wall chart and recording the number of correct letters read.

    Time frame: Baseline/Day 1 through Month 24

  5. Change in Standard luminance manifold contrast vision meter contrast sensitivity (MCVM-CS) scores in the early/intermediate AMD eye

    MCVM contrast sensitivity measurements will be performed using an automated device that uses an adaptive algorithm to rapidly measure a contrast sensitivity function in 5-10 minutes.

    Time frame: Baseline/Day 1 through Month 24

  6. Pharmacokinetics - concentrations of LNP023 related to trough samples

    Bioanalytical determination of plasma LNP023 concentrations related to trough samples using a LC-MS (mass spectrometry) method.

    Time frame: Baseline/Day 1 through Month 24

  7. Change in low luminance manifold contrast vision meter (MCVM) contrast sensitivity scores in the early/intermediate AMD eye

    MCVM contrast sensitivity measurements will be performed using an automated device that uses an adaptive algorithm to rapidly measure a contrast sensitivity function in 5-10 minutes.

    Time frame: Baseline/Day 1 through Month 24

07

Study locations

28 sites
  • Retina Consultants of Orange County
    Fullerton, California 92835, United States
  • Salehi Retina Institute
    Huntington Beach, California 92647, United States
  • Martel Eye Medical Group
    Rancho Cordova, California 95670, United States
  • Retinal Consultants Medical Group Inc
    Sacramento, California 95841, United States
  • California Retina Consultants
    Santa Barbara, California 93103, United States
  • Southwest Retina Research Center
    Durango, Colorado 81303, United States
  • Advanced Research LLC
    Deerfield Beach, Florida 33064, United States
  • Retina Center Of South Florida
    Delray Beach, Florida 33484, United States
  • Retina Vitreous Associates of Florida
    St. Petersburg, Florida 33711, United States
  • Midwest Eye Institute
    Carmel, Indiana 46032, United States
  • Retina Associates New Orleans
    Metairie, Louisiana 70001, United States
  • Retina Care Center
    Baltimore, Maryland 21209, United States
  • Opthamalic Consultants of Boston
    Boston, Massachusetts 02114, United States
  • Envision Ocular LLC
    Bloomfield, New Jersey 07003, United States
  • Duke Eye Center
    Durham, North Carolina 27705, United States
  • Retina Northwest PC
    Portland, Oregon 97210, United States
  • Charles Retina Institute
    Germantown, Tennessee 38138, United States
  • Austin Research Center for Retina
    Austin, Texas 78793, United States
  • Retina Consultants TX Rsrch Ctr
    Bellaire, Texas 77401, United States
  • Retina Foundation
    Dallas, Texas 75231, United States
  • Texas Retina Associates
    Fort Worth, Texas 76104, United States
  • Retina Consultants of Houston PA
    Houston, Texas 77030, United States
  • Novartis Investigative Site
    Harbin, Heilongjiang 150001, China
  • Novartis Investigative Site
    Tianjin, Tianjin Municipality 300020, China
  • Novartis Investigative Site
    Shanghai, 200080, China
  • Emanuelli Research and Development Center LLC
    Arecibo, 00612, Puerto Rico
  • Novartis Investigative Site
    London, SE5 9RS, United Kingdom
  • Novartis Investigative Site
    Southampton, SO16 6YD, United Kingdom
08

References and documents

Publications

  • Tzoumas N, Riding G, Williams MA, Steel DH. Complement inhibitors for age-related macular degeneration. Cochrane Database Syst Rev. 2023 Jun 14;6(6):CD009300. doi: 10.1002/14651858.CD009300.pub3. PubMed 37314061 ↗

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

Data sharing details ↗ · clinicalstudydatarequest.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in Aug 2026, 54 months.

Of 66 industry-sponsored phase 2 interventional studies under Macular Degeneration, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 54 months is above that.

Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 16 and three quarters within 35.

Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Aug 2026, on Oct 27, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2022
First posted
Feb 9, 2022
StartActual
Feb 17, 2022
Primary completionActual
Aug 19, 2026was Sep 2026
CompletionActual
Sep 30, 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 27, 2026
Primary completion
Sep 30, 2026→Aug 19, 2026 (actual)
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Active, not recruiting→Completed
    Primary completion Sep 30, 2026→Aug 19, 2026 (now actual)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05230537
Responsible party
Sponsor
First posted
Feb 9, 2022
Start date
Feb 17, 2022
Primary completion
Aug 19, 2026
Completion
Sep 30, 2026
Last update
Oct 27, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iptacopan

Start the discussion